醫藥 - 2021 SAPA-NE年會 10/15

2021 SAPA-NE and SAPA-CT Joint Annual Conference

Lynk Pharmaceuticals announced the completion of Series B financing of $50 million 


Lynk Pharmaceuticals Co., Ltd.

2021-08-27 08:00  1848

 Lynk Pharmaceuticals announced the completion of Series B financing of $50 million - PR Newswire APAC (prnasia.com)

HANGZHOU, ChinaAug. 27, 2021 /PRNewswire/ -- Lynk Pharmaceuticals CO., LTD (hereinafter referred to as "Lynk Pharmaceuticals"), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of $50 million, with Lilly Asia Ventures (LAV) as lead investor, New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) as co-investors, and its original shareholders Legend Capital and Med-Fine Capital as participating investors. The proceeds from this round of financing will mainly be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline of Lynk Pharmaceuticals. In addition, the funding will be used to expand international business, strengthen international collaborations with leading companies and support preclinical development of new projects. CEC Capital acted as the exclusive financial advisor to Lynk Pharmaceuticals in this transaction.

Founded in 2018, Lynk Pharmaceuticals is a globally leading innovative drug R&D company. Based on the team's world-leading experience in medicinal chemistry and small molecule clinical development, it is dedicated to the development of global FIC/BIC small molecule drugs for autoimmune diseases, inflammation and cancers. In three and a half years since its establishment, Lynk has obtained IND approvals for three original products in China and the United States, launched global clinical development efforts, and completed the ex-Chinese rights out-license of LNK01001 to a US company and the in-license of the first-in-class RAS program from Japan's Kobe University and RIKEN, both in 2020.

Dr. Zhao-Kui (ZK) Wan, Chairman and CEO of Lynk Pharmaceuticals, said, "We are very much grateful for the recognition and support from the top investors in the industry. Since the establishment of Lynk Pharmaceuticals, we have been advancing our projects with efficient execution, and we have made significant progress in just three and a half years. This round of financing will lay a solid foundation for us to further develop our pipeline and continue to advance innovative therapies. Owing to the great efforts of many scientists and investigators, I believe that we will benefit patients with innovative therapies as soon as possible."

According to Dr. Ting Feng, Vice President of Lilly Asia Ventures (LAV), "We are deeply impressed by the efficient execution and global vision of Lynk Pharmaceuticals' management team. We are also very optimistic about the future huge market space and the unmet patient needs in the field of autoimmune disease and cancer. We are excited to partner with the Lynk team to accelerate its growth and look forward to more breakthroughs and successes in the future with our innovation capability."

Lei Cai, Managing Director at New Alliance Capital, commented"there have been huge unmet needs as well as great potential for small molecule drugs to treat autoimmune disease and cancer. Lynk's international vision and strong team execution have left a deep impression on us; we are very happy to have the opportunity to work with Lynk. New Alliance Capital will provide full support in all aspects of capitals and industry resources to support the company to become a global leader and bring more effective solutions to benefit patients across the world."

[This Thu] SAPA-NE 2021 Bimonthly Workshop

July 22, 2021, Thursday, 8:30 PM - 10:00 PM EDT



Dear SAPA-NE Members and Friends,

The Sino-American Pharmaceutical Professionals Association–New England/Boston (SAPA-NE) is glad to announce that SAPA-NE 2021 Bimonthly Workshop, 
Recent Individual Tax Development in the US and China, will be held in 4 days. The workshop will be presented by EY China overseas investment, people advisory services. This event will be held virtually on Thursday, July 22, 2021 and will be delivered in Mandarin.


Please contact us at info@sapa-neweb.org if you have any membership or registration-related questions. 


Agenda Topics


·       US individual tax filing and disclosure requirements

·       Outlook for Biden’s proposed tax plans on impacts on individuals

·       US expatriation rules for US citizens and green card holders

·       China individual income tax reform and annual tax filing requirements

·       Individual tax planning considerations, such as US citizens and greencard holders working / investing in mainland China

·       Q&A 

July 22, 2021, Thursday, 8:30 PM - 10:00 PM EDT


How to become a SAPA-NE Member?

Paid Membership Rate

Student & Postdoc (Annual): $15

Professionals (Annual): $30

Life-time: $300

Note: Paid membership will be effective immediately after purchase

 BIO Digital Taiwan Day

Accelerating Biotech innovation through global collaboration with healthcare, VC and though leaders

About this event

Taiwan Start-up Pitch

Chung-Chu Chen, CEO of Somnics

Ed Deng, Health2Sync

Panel 1 : Post-COVID Solution and Challenges in Healthcare

Salman Al-Sabah, Chairman of Surgery of Jaber Al-Ahmad Al-Sabah Hospital, Kuwait

Helen Chen, CMO of Hewbrew SeniorLife

Peter Lee, Medical Director, Amazon

Po-Shun Lee, CMO of PlateletBio

Panel 2 : Digital Transformation with Pharma

Tony Chan, Morgan, Lewis & Bockius, Partner and Leader, DC Corporate Group

Robert Lake, Managing Director, Runway Growth Capital

Kevin Lalande, Santé Ventures, Founding Managing Director & CIO

Sandeep M Menon, SVP and Head of Early Clinical Development, Pfizer Tony Chan, Partner, Morgan Lewis

𝐁𝐓𝐁𝐀 𝟐𝟎𝟐𝟏 𝐀𝐧𝐧𝐮𝐚𝐥 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦
July 10 & 11 (Saturday and Sunday) 2021
12:50 pm to 6:30 pm EDT
Eventbrite: ibit.ly/AZSJ
**Free event! Space is limited, REGISTER TODAY!**
[Webinar link and password will be sent to you on 7/10/2021 morning]
This online symposium will bring experts from academia and industry to share their experiences and knowledge on their research/responsibility, personal career development, and lessons learned for young scientists. This year, we are honored to have Dr. Herren Wu, Ph.D., the Senior Vice President of AstraZeneca, and Dr. Jeannie T. Lee, M.D., Ph.D., Professor of Genetics of Harvard Medical School.
𝐊𝐞𝐲𝐧𝐨𝐭𝐞 𝐒𝐩𝐞𝐚𝐤𝐞𝐫𝐬
𝑯𝒆𝒓𝒓𝒆𝒏 𝑾𝒖, 𝑷𝒉.𝑫. | 𝐒𝐞𝐧𝐢𝐨𝐫 𝐕𝐢𝐜𝐞 𝐏𝐫𝐞𝐬𝐢𝐝𝐞𝐧𝐭 𝐨𝐟 𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚
𝑱𝒆𝒂𝒏𝒏𝒊𝒆 𝑻. 𝑳𝒆𝒆, 𝑴.𝑫., 𝑷𝒉.𝑫. | 𝐏𝐫𝐨𝐟𝐞𝐬𝐬𝐨𝐫 𝐨𝐟 𝐆𝐞𝐧𝐞𝐭𝐢𝐜𝐬 𝐨𝐟 𝐇𝐚𝐫𝐯𝐚𝐫𝐝 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐒𝐜𝐡𝐨𝐨𝐥
𝐀𝐛𝐨𝐮𝐭 𝐁𝐓𝐁𝐀
As a non-profit organization, we appreciate your consideration of giving a small gift to support BTBA! Your donation qualifies for tax-exemption and grants you guaranteed access to the 2021 BTBA Virtual Symposium meeting rooms.
*Keynote, academia, and industry sessions will be conducted in English*


Dear SAPA-NE members:


We are pleased to inform you the result of the SAPA-NE leadership election in 2021 as below:

James Jianming Chao

Secretory general:
Kehao Zhao

The team is looking forward to working closely with you to build the community together!

2021 Election Committee

The 22nd SAPA-NE Annual Conference

A New Era in Biotech and Life Science


Sat, Jan 23 | Free Zoom Webinar

9:00 AM – 6:00 PM EST

Seats are limited

Please register ASAP

Time: Sat, Jan 23rd, 9:00 AM – 6:00 PM EST

Language: English

Venue: Zoom Webinar, Spatial Chat (Virtual Networking, Job Hunting, Vendor Show)

Speakers & Presentation Topics


Morning Sessions: 9:00AM-12:30PM

Noon Sessions: 12:30PM-2:00PM

Afternoon Sessions: 2:00PM-6:00PM

Speaker Bio

Dan Barouch, M.D., Ph.D.

Member, National Academy of Medicine; William Bosworth Castle Professor of Medicine, Harvard Medical School; Director, Center for Virology and Vaccine Research, BIDMC; Member, Ragon Institute of MGH, MIT, and Harvard

Eric Fischer, Ph.D. 

Eric Fischeris an Independent Investigator at Dana-Farber Cancer Institute, Associate Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School, and Co-Director of the DFCI Center for Protein Degradation. He and his lab have significantly contributed to our understanding of small molecule mediated protein degradation, and its widespread application in academia and industry. Dr. Fischer has co-founded Civetta Therapeutics, Jengu Therapeutics, and Neomorph and serves on the scientific advisory board for the Institute for Protein Innovation.

John Evans, MBA

John Evans joined Beam in 2017 as CEO, bringing significant experience as a company builder, dealmaker, and drug developer in the biotechnology industry. Mr. Evans is also a Venture Partner with ARCH Venture Partners.

Mr. Evans was previously an early employee and member of the leadership team at Agios Pharmaceuticals, most recently serving as Senior Vice President for Corporate Development and Portfolio Leadership. Prior to joining Agios, Mr. Evans worked at Infinity Pharmaceuticals, McKinsey & Company (Pharmaceuticals practice) and MedImmune.

Mr. Evans holds an M.B.A. in Healthcare Management from Wharton, a Masters in Biotechnology from the University of Pennsylvania, and a B.A. in English with distinction from Yale University.

Jamie Stokes, Ph.D.

Jamie received his PhD from University of Cambridge in 2014. Between 2014 and 2017 Jamie was a Roche Postdoctoral Research Fellow at Cambridge where he worked on a number of projects at the chemistry-biology interface including the design and synthesis of de-novo antibiotic-quorum sensing small molecule conjugates and the development of methodology to allow access to diverse collections of small molecule screening collections. Jamie has worked at Concept Life Sciences since 2017 on a number of different medicinal chemistry programs and has a special interest in new approaches to synthesis and antibody drug conjugates.

Zonghai Li, M.D., Ph.D.

Zonghai Li is the Chairman, Chief Executive Officer, Chief Scientific Officer and Founder of CARsgen Therapeutics. He is dedicated himself to develop curable treatment for the patients with cancer. One of his early career achievements is the identification of GE11, a peptide ligand of EGFR which has become one of the most widely used peptides in antitumor study now. He has a leading role in the research on CAR T cell therapy against solid tumors by publishing the first paper and advancing the first clinical trial of CAR T cell therapy against GPC3, Claudin18.2 and EGFR/EGFRvIII worldwide. He earned a M.D. and M.S. from Xiangya Medical School of Central South University and a Ph.D. from Fudan University.

Liang Schweizer, Ph.D.

Liang Schweizer is the co-founder, President and CEO of HiFiBiO Therapeutics, an emerging multinational biotherapeutics company. Previously, she was a co-founder and CSO for Harbour Biomed. Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi and Director of Leads Evaluation at Bristol-Myers Squibb Company. Under her leadership, her various teams made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple immunomodulation drug candidates.

Dian Su, Ph.D.

Dian is a Senior Scientist in Drug Metabolism and Pharmacokinetics (DMPK) at Genentech. Her research focus has been on ADC/small molecule/peptide DMPK areas mainly in the pre-clinical stage. At DMPK, her primary focus lies in small molecule and peptide drug metabolism in discovery stage. In this role, her responsibilities include: 1) developing new generation assays for metabolite identification (Met ID) to improve the throughput and tackle challenges associated with drug metabolite ID; 2) exploring deep understanding of metabolite formation and biological impact, and establish structure−metabolism relationship (SMR) for drug metabolites. 

Yan Chen, Ph.D. Founder, President and CEO of Elpis Biopharmaceuticals

Yan brings more than 20 years of expertise in both mRNA display technology and biologic drug discovery in the oncology disease area. She was Biotherapeutics Discovery Head at Juno Therapeutics in Boston and Senior Vice President of Research at X-Body Biosciences which was acquired by Juno in 2015. Previously, she was an investigator and project leader in Oncology Biotherapeutics at Novartis Institutes for Biomedical Research. Earlier in her career, she was a scientist at Phylos and Adnexus playing instrumental roles in establishing the mRNA antibody and protein display technology platforms. Yan was a postdoctoral trainee in Immunology at Tufts Medical School and received her PhD in Tumor Immunology from National University of Singapore. She is the co-inventor of more than 20 antibody technologies and biologic therapeutics patents.

Sanchayita Ghose, Ph.D.

Sanchayita Ghose is currently the Executive Director of Global Downstream Bioprocess Development at Bristol Myers Squibb.  She leads a multi-site team responsible for downstream process development of BMS’ entire clinical biologics portfolio. Sanchayita has > 20 years of experience in bioprocess development with increasing roles of responsibility in a variety of biopharmaceutical companies: BMS (9), Amgen (6), Biogen (5). Over her career, she has made numerous technical contributions in this field and is the author of > 100 conference presentations, publications, book chapters and patents. She has a PhD in Chemical & Biological Engineering from Prof. Steve Cramer’s lab at Rensselaer (Troy, NY) and a BS in Chemical Engineering from Jadavpur University, India. Sanchayita is the mom of two-school aged kids and has lived if four US states across both coasts. In her free time, she enjoys travel, reading and hiking.

Brad Warsen

Brad Warsen is the Executive Director of Quality for the Devens Cell Therapy Facility at Bristol Myers Squibb.  Brad joined Bristol Myers Squibb in 2013 and previously served as the Head of Quality for US Biologics overseeing quality operations at the Devens and Syracuse sites.  Previous to this, he served as the Director of Quality at Devens, interim Director of Quality at Syracuse and as head of Quality Control Operations and Quality Assurance Operations both at Devens.  Brad has over 20 years of quality experience and previously served in quality leadership roles overseeing external manufacturing of biologics drug product at Shire and internal manufacturing of drug substance at Pfizer (including raw materials, compliance and QA Operations roles).  Brad began his career in manufacturing and process development at Pharm-Eco Laboratories and has a BS in Chemistry from Wheaton (IL) College.

Ji Li, Ph.D.

Ji Li is a Principal Scientist at BMS Kendall square site, Mechanism of Cancer Resistance TRC. He currently services as the Biology Lead for two drug discovery projects. He also leads a DepMap data analysis effort and leverages a genome-wide CRISPR screening platform to discover novel cancer targets. Prior to BMS, he worked at the Broad Institute and Dana-Farber Cancer Institute, where he led efforts in functional cancer genomics and the identification of synthetic lethality in breast cancer. Ji received his Ph.D in Cell Biology from NYU School of Medicine and a Bachelors’ degree in Biomedical Sciences from Peking University.

Chun Shao, Ph.D.

Chun Shao is a Principal Scientist at BMS Devens site, who joined Bristol-Myers Squibb in 2018. Chun interfaces closely with biologics process development upstream/downstream team and provides mass spec analytical support for bioprocess optimization. Chun is also co-leading Devens PAN chapter to drive Diversity & Inclusion initiatives. Prior to BMS, Chun worked at GlaxoSmithKline between 2016 and 2018 as characterization lead to support biologics process development. Chun received her PhD degree in Biochemistry from Boston University in 2016.  Chun is a big fan of Boston Celtics and Bruins and looking forward to shouting out loudly in TD garden soon with crowds!

Robert Flaumenhaft, M.D., Ph.D.

Dr. Flaumenhaft is a Professor of Medicine at Harvard Medical School and Chief of the Division of Hemostasis and Thrombosis. His laboratory focuses on endothelial & platelet biology and mechanisms of thrombus formation. Dr. Flaumenhaft is director of the T32 training program, “Blood Coagulation and Vascular Biology” and has editorial positions at Blood, JCI Insight, Thrombosis and Haemostasis, Thrombosis Research, and Seminars in Thrombosis and Hemostasis. He is Chairperson of the Hemostasis, Thrombosis, Blood Cells, and Transfusion NIH Study. He was the scientific co-chair of the ASH 2019 meeting and was the Chairman of the FASEB meeting on Functional Disulfide Bonds in Health and Disease. He has received awards from the Burroughs Wellcome Fund, the American Society of Hematology, and the American Heart Association. He was elected to the American Society for Clinical Investigation and subsequently to the American Association of Physicians. He is the recipient of an Outstanding Investigator Award from NIH.

Ai-Min Hui, MD, Ph.D. President of Global R&D, CMO, and Chair of the Scientific Committee of Fosun Pharma;Director of Shanghai Key Laboratory of Stem Cell Therapy; Former global Vice-President of Clinical Development Oncology at Sanofi

   Dr. Hui has 30 years of experiences in cancer treatment and innovative drug development in world's top medical centers and pharmaceutical companies. He has led the global development and registration of multiple small molecule and biologic anti-cancer drugs including Ixazomib, Isatuximab (anti-CD38) et al. He has recently led the deal of the joint development of an mRNA vaccine against COVID-19 BNT162 between BioNTech and Fosun Pharma and the execution of the program.

Julia Ding, Ph.D.

Julia Ding is leading process analytical development at Bristol Myers Squibb biologic development sites in US. She is leading diverse and cross-functional teams responsible for: Establishing strategic vision and implementation of global biologic PAT and rapid analysis technology development; Establishing and advancing new technologies in PAT and real-time release of biologic process; Developing and implementing analytical methodologies to enable and support bioprocess development and characterization; Advancing analytical CMC control strategies throughout biologic clinical development phases.

Prior to joining Bristol Myers Squibb, Julia Ding led a multifunctional analytical development team responsible for analytical assay development/validation/life cycle management, characterization and cGMP quality control testing of biologic products at PPD. Julia obtained her Ph.D. in physical organic chemistry from Emory University and postdoc from University of California at Berkeley.

Qingcong Lin, Ph.D.

Dr. Qingcong Lin is SVP of Biocytogen and CEO of Biocytogen Boston Corporation, focusing on providing services on gene-targeting and humanized mouse models, using cutting-edge ESC and CRISPR-Cas9 technology for immuno-oncology antibody candidate in vivo efficacy and toxicity assessment. Prior to joining Biocytogen, Dr. Lin was SVP of Shenogen Pharma Group. Dr. Lin has extensive expertise in multiple therapeutic areas, including cancer, CVMD, neurology, immunology & inflammation and various technologies, including genetically engineered mouse models, therapeutic antibody engineering, affinity maturation and optimization. Prior to joining Sheongen, Dr. Lin worked at Pfizer as a principal research scientist II and group leader of antibody engineering group. Before joining Pfizer, he worked at Wyeth and Harvard Medical School as Director of Gene Modification Lab of Harvard-Partners Center for Genetics and Genomics. Dr. Lin received Ph.D. from Albert-Einstein College of Medicine and completed his postdoctoral training at Harvard Medical School.

Ambar Boodhoo
Ambar is Americas Life Sciences Strategy and Transactions Leader at EY. He advises life sciences and health care clients on their capital and transaction agendas from strategy through execution, primarily focusing on large, complex investments. Over the last 20 years, he has supported private equity funds and corporate clients in transformational transactions to realize their strategic objectives and improve growth. His experience includes financial and operational diligence in taking companies private, leveraged recapitalizations, carve-outs, rollups, divestitures, PIPE and public financing. He has worked extensively in the UK and the US, and has led global engagements with clients and transaction teams in Europe, India, the Middle East and Asia.

Alex Li, Ph.D. Managing Director of TF Capital

Board Director of SAPA, previous president of SAPA-NE

Dr. Alex Li is a venture capital investor with investing experience in both United States and China. He specialized in the life science industry with focus on cutting edge technology and first-in-class therapeutic medicine. He currently serves on the boards of five innovated companies. TF Capital, one of the premium venture capital fund in China, have invested in near 100 companies, with successful exits like Zai Lab, Hua Medicine, Henlix, and Frontage, etc. Alex is one of the three investment decision committee members in TF Capital. Before Joining TF Capital, Alex was Managing Director of Fosun Pharma for three years. Alex worked as a research scientist in Biogen for seventeen years. Alex obtained his Ph.D. degree in Biochemistry, Cellular and Molecular Biology (BCMB) from the University of Tennessee.

How to become a SAPA-NE Member?

Paid Membership Rate

Student & Postdoc (Annual): $15

Professionals (Annual): $30

Life-time: $300

Note: Paid membership will be effective immediately after purchase.

2021摩根会议周期间 SAPA与BioNJ联合推出网络研讨会(链接更新)


2021年J. P. Morgan会议周期间, 美中药协SAPA与BioNJ将联合推出网络研讨会,关注医药领域美中企业间的合作。












1月14日, 2021
8:30-10:30 AM EST







Modified on 2021-01-10
2020 SAPA-NE Career Development Webinar















































2020年12月2日 8:00 PM - 9:00 PM 
(EDT, 美国东部时间)








Jason S French

Managing Director, People Advisory Services

Jason is a Managing Director in the People Advisory Services practice of EY, with 15 years of experience related to the analysis, design and implementation of compensation and benefit matters for both US domestic and internationally mobile employees. Jason’s areas of expertise are specifically within the compensation and benefits space for both US and multinational companies around the globe, equity compensation, global equity, golden parachutes, annual & long-term incentive plan and design, payroll and tax withholding, and US tax technical matters. Jason also advises companies on SEC Executive Compensation Proxy Disclosure rules and director compensation matters.

Claudia Timmermans

Senior Manager, People Advisory Services

Claudia has over 8 years of experience advising clients regarding (global) compensation and benefits arrangements. Claudia has significant experience on assisting clients with maximizing the benefits of equity compensation plans for mobile employee workforces, which includes advising clients on equity plan design and implementation, tax feasibility and due diligence, risk mitigation, global payroll transformation and employee education. She also advises clients on the implications of Internal Revenue Code Sections 162(m), 280G (golden parachutes), 409A, and 457A. 

点击阅读原文(Read More) 进入注册链接 

Read more
Reads 272

2020 CABA Boston BioForum Online

 Jo Lee CABA 




在疯狂的2020年压抑了太久,CABA Boston BioForum Online将于12月19日举行,为这不平凡的一年做个强势收官,总结COVID-19带来的危与机,预测生物医药投资趋势,并展望美中两个大经济体生物医药业的未来。会议邀请了数位行业大咖与大家齐聚线上,与您分享探讨2020年生物医药大事件!




Chuan He, PhD, Professor, HHMI, University of Chicago

RNA Methylation in Human Diseases

Speaker Bio:

Dr. He is the John T. Wilson Distinguished Service Professor in the Department of Chemistry and Department of Biochemistry and Molecular Biology at the University of Chicago. He received his bachelor of science degree in 1994 from the University of Science and Technology of China and his Ph.D. in chemistry from the Massachusetts Institute of Technology in 2000, studying under professor Stephen J. Lippard. After training as a Damon-Runyon postdoctoral fellow with professor Gregory L. Verdine at Harvard University, he joined the University of Chicago as an assistant professor, rising to associate professor in 2008 and full professor in 2010. He was selected as an investigator of the Howard Hughes Medical Institute in 2013. Dr. He’s research spans a broad range of fields including chemical biology, RNA biology, epigenetics, biochemistry, and genomics. His recent research concerns reversible RNA and DNA methylation in biological regulation. In 2011, his group discovered reversible RNA methylation as a new mechanism of gene expression regulation. His laboratory has spearheaded the development of enabling technologies to study the biology of RNA and DNA modifications.


Robert DeLuccia, 

Managing Partner and Founder, Acurx Pharmaceuticals

Acurx Developing a New Class of Antibiotics: Preparedness for the Next Infectious Disease Pandemic, Antimicrobial Resistance

Speaker Bio:

Bob DeLuccia has 50 years’ executive and hands-on experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Mr. DeLuccia has held senior executive positions in both companies and has also been Chief Executive Officer of two publicly (NASDAQ) traded biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP). He was most recently Executive Chairman of publicly-traded (NASDAQ) Dipexium Pharmaceuticals, Inc., a development-stage biopharmaceutical company based in New York City which he co-founded and subsequently took public. In April, 2017, Dipexium closed a merger with PLx Pharma Inc. (PLXP-NASDAQ), a late-stage specialty pharmaceutical company focused on developing AspertecTM, its aspirin product in its proprietary PLxGuardTM drug delivery system to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy and better tolerated treatment. He is currently Co-Founder and Managing Partner of Acurx Pharmaceuticals, a New York-based, development-stage biopharmaceutical company focused on developing a new class of antibiotics to treat common infections caused by certain Gram- positive bacteria and to combat the global crisis of antimicrobial resistance (AMR) to currently available antibiotics. He is also a member of the Board of Directors of IBEX Pharmaceuticals, a publicly- traded (IBT.V/TSXV.IBT), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use and arthritis assays widely used in osteoarthritis research. 

His therapeutic areas of marketing experience include new product introductions and drug development in the following areas: Antibiotics and antidiabetic agents: (doxycycline, bacampicillin, cefaperazone, chlorpropamide and glypizide); Cardiovasculars: amrinone, iohexol contrast media, clopidogrel. New drug development areas included: topical creams/gels for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection. 

Mr. DeLuccia received his undergraduate degree and MBA from Iona College, New York. Military Service, Officer, U.S. Army Corps of Engineers. 


Ricky Sun, PhD, Partner, Bain Capital Life Sciences

Life Science Investing, a Global Perspective

Speaker Bio:


Dr. Sun joined Bain Capital Life Sciences in 2016 and is a partner. He is currently a member of the Board of Directors of Arcutis (NASDAQ: ARQT), Annexon (NASDAQ: ANNX), and Savara (NASDAQ: SVRA). He is also a board observer of Pharvaris. Previously he also served as a board observer for Replimune (NASDAQ: REPL).

Prior to joining Bain Capital, from 2013 to 2016, he was a Director of Corporate Development and Strategy at Biogen. Prior to Biogen, Dr. Sun served as a Vice President at BlackRock, as a member of the Fundamental Equity division of BlackRock's Alpha Strategies Group and senior analyst for BlackRock's Fundamental Large Cap Growth equity team, covering the health care sector. Prior to that, he was a senior healthcare analyst at Citadel and Alyeska Investment Group in Chicago and worked as a pharmaceuticals equity research analyst on Wall Street, spending time at Lehman Brothers and Morgan Stanley. Dr. Sun began his career as a senior scientist at Ironwood Pharmaceutical where he was involved in the discovery and development of the drug Linzess for irritable bowel syndrome.


Dr. Sun received a PhD degree in Chemistry and Chemical Biology from Harvard University and was an NIH post-doctoral fellow in Biological Chemistry & Molecular Pharmacology at Harvard Medical School.  He also received an MBA from New York University Stern School of Business, where he was a Mildred Elperin Scholar.  He graduated summa cum laude from Berea College with a BA in chemistry.


Chris Garbedian, CEO, Xontogeny

Venture Investment in Rare Diseases

Speaker Bio:

Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.


Angus Grant, PhD, Chief Business Executive, BeiGene

Building Portfolio with Business Development Support for China

Speaker Bio:

Angus Grant, Ph.D., joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr. Grant will oversee business development and alliance management, and help drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining us, Dr. Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr. Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr. Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the U.S. Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr. Grant received a bachelor’s degree from the University of Richmond and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.



Join Zoom Meeting

Meeting ID: 879 9988 3589

Passcode: 498231


CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.

Chinese-American BioMedical Association


 哈佛中国健康协会 Harvard Healthcare Club 



医路领航研讨会 第四期



我们很荣幸地邀请到了两位来自数字化精神健康治疗领域的发展先驱公司的演讲嘉宾,与我们分享他们的公司愿景,以及他们对数字化精神健康治疗未来的看法:Paul Dagum博士(Mindstrong的创始人和前首席执行官),Sharief Taraman博士(Cognoa首席医务官。Cognoa专注于儿童神经发育障碍的治疗,例如自闭症和注意缺陷与多动障碍;Mindstrong关注对严重的精神障碍的治疗。



Dr. Paul Dagum

Mindstrong是一家医疗创新公司,以Mindstrong的创始人,副董事长兼首席科学官Paul Dagum博士的前瞻性研究作为基础。Mindstrong致力于通过数字化测量,利用数据科学和线上护理模型的创新来改变精神健康状态。


Mindstrong提供的解决方案和健康服务有助于在护理过程中抢得先机以改善治疗效果。他们得到了ARCH Venture Partners,General Catalyst,Foresite Capital,Optum Ventures,8VC等投资公司的支持。


Paul Dagum博士是Mindstrong的创始人,并在2019年11月前一直担任其首席执行官。他是一位企业家,也是医师和计算机科学家,他曾作为创始人、首席科学官、首席技术官和首席执行官,将产品、技术和商业模式的创新引入医疗健康、网络安全和供应链领域,并受到了多家知名风险投资公司的支持。Dagum博士对动态贝叶斯网络的早期研究已在许多现代应用中使用。他还开发了用于数据科学的大规模可扩展算法,应用于大量世界领先的数据公司,以及通过从移动设备被动捕获的人机交互中,创建了首个脑功能数字化量度技术,两者均获得了专利。同时,Dagum博士也在持续测量技术和人工智能赋能的远程医疗基础上,设计了用于精神健康的数字化护理模式。




Dr. Sharief Taraman




医学博士Sharief Taraman获得了神经病学领域的双重认证,包括美国精神病学委员会的儿童神经病学和美国预防医学委员会的神经病学及临床信息学的专业资格认证。他是CHOC儿童专科学院的儿科神经病学系主任,也是加州大学欧文分校医学院的临床副教授






Mindstrong - Paul Dagum, MD, PhD

Cognoa - Sharief Taraman, MD


Zoom 直播


美东时间: 11月21日 8:00-9:00 pm

美西时间: 11月21日 5:00-6:00 pm

北京时间: 11月22日 9:00-10:00 am





统筹:茅傲岳 朱子溪 闫姿秀 王目阔 

王硕 王紫 戴钰


美编:王紫 朱霁清



医路领航研讨会(Frontier Healthcare Cross Talk)以激励创新技术转化为目的,以研讨会为载体,邀请中美的顶级投资人、头部企业、优秀创业公司、及来自哈佛、MIT等的专家学者,帮助哈佛及友校的学生学者群体跟踪最实用的前沿医疗产业动态,协同中美医疗业界掌握最干货的前沿科学研究成果。通过定期跨学科、跨领域的不断探讨,共同助力技术创新上、中、下游的对接与耦合。







波士頓台灣人生物科技協會 (BTBA) 與哈佛台灣學生會 (HTSA) 將合作舉辦「綠卡&H1B申請線上講座與經驗分享」,邀請綠楓法律集團創所律師陳啟耕律師 (Danny Chen) 主講綠卡及H1B申請的過程,並邀請三位不同身份轉換取得綠卡的學長姊分享自身經驗。本講座將包含以下主題:

- 各種身份 (F, J, OPT)如何銜接轉換綠卡或H1B?
- 何種條件、時機可以開始申請綠卡?要累積什麼經驗、資歷對申請綠卡有幫助?
- EB1、EB2申請難度及條件?
- 學長姊過來人經驗分享,若時光倒流他們會/不會做的事是什麼?
- 近期移民政策對申請綠卡、H1B的影響


[活動分享] BTBA monthly Seminar!
BTBA Monthly seminar is back! We are happy to have two outstanding scientists from the Harvard community to present their recent work.
*Kai-Ting Shade (Instructor, Massachusetts General Hospital)
"Sialylation of immunoglobulin E is a determinant of allergic pathogenicity"
*Annie Cheng (Postdoc, Brigham and Women's Hospital)
"Nanoparticles: A multifunctional vehicle for theranostics"
Moderator: Jerry Lin (Postdoc, Massachusetts General Hospital)
Meeting link coming soon!

BTBA-Boston Taiwanese Biotechnology Association
要來舉辦2020-2021 Welcoming party!!
走過路過不要錯過~ 派對上我們要一起來討論接下來新活動內容,另外也想聽取大家的意見跟未來活動喜好。相較於過往的學業界活動,新的一年我們還有新面向的互動方式喔~ 希望在這個疫情期間,BTBA的大家可以透過迎新趴認識一下新來到波士頓的朋友,還有一路陪伴的老朋友們!
滑鼠往下按連結就可以報名參加這次的迎新派對了! 希望下週日可以線上見囉! 如果有任何問題歡迎聯絡今年負責人
22021 BTBA VIy
We are excited to invite everyone to come and join 2020-2021 Boston Taiwanese Biotech Association (BTBA) Virtual Welcome Party on September 13, 2020!

Hope everyone is well, healthy, and safe during the pandemic. As the new school year arrived, BTBA welcomes everyone who calls Beantown a new home to join our virtual welcome party on September 13, 2020! No matter you are an academic professional, a biotech professional, a postdoctoral researcher or a student, we sincerely invite you to come and connect with us. At BTBA, you will find a group of passionate scientists and enthusiasts to network and discuss career opportunities & possibilities, healthcare related topics, life science research, pharmaceuticals, drug discovery start-ups as well as the innovation and technology that powers it all.
We thrive because of you!
We are thrilled to get to know you, so come and join us!

各位親愛的朋友,大家好!希望大家在COVID期間都健康平安! 新的學年又要開始囉!波士頓台灣人生物科技協會 (BTBA) 今年的第一場活動將在 9月13日 登場~! 歡迎新朋友&老朋友一起來互相認識,不管是來念書,來工作,來當Postdoc,都不要錯過BTBA的活動。不是生物領域,也沒有問題!來聽聽看新的一年可以有甚麼精彩可期的活動!

時間 / Time:
2020-09-13 (Sun) 1 pm - 3 pm

地點 / Place:
Microsoft Team Meeting
Meeting link will be sent separately, please make sure leave your e-mail below!

聯絡人 / Contact:
Yvonne Meng 孟憲薇; hsienweimeng@gmail.com
Erica Cai 蔡佩珊; ericapscai@gmail.com

Please complete this form to RSVP (Registration is free!).

Follow & Like us on Facebook: https://www.facebook.com/btbatw/

會議流程 / Event:
1:00 am – 1:30 pm Meet and Greet
1:30 pm – 2:00 pm BTBA Introduction
2:00 pm – 3:00 pm Networking

美中藥協年度科學盛會【2020 SAPA科學論壇】將於8月15日(星期六)以網絡會議形式舉行。

今年主題是“生物醫學創新轉型的驅動力”,將重點關註生物醫學創新在🩺診斷與精準醫學,🧬細胞與基因療法,以及藥物研發的新技術等領域的最新趨勢與突破。世界知名的科學家,包括哈佛大學的George Church教授和斯坦福大學的Richard N. Zare教授,以及諸多製藥行業領導者、科學家和企業家,將分享他們對生物醫學創新的思考與見解。 🔛論壇還設有互動交流小組會議,提供了同主講人和資深業內人士在線面對面交流的機會。
SAPA會員福利免費註冊 ,學生註冊享優惠!
⏰時間:2020年8月15日 週六 9:00 AM-5:00 PM EDT

2020 BTBA Virtual Symposium in two weeks!!!
This year, we are honored to have Dr. Taiyin Yang, the Executive Vice President of Gilead Sciences, who supervised the development of Remdesivir, to deliver the keynote address.
Please also check out the rest of meeting agenda!
*Flyer designed: Amy Kao

7月11日 OCEAN-BIO SEMINAR:中美投资并购中的国家安全审查和出口管制问题

 OCEAN BIO 海华会生物分会 2 days ago
2020年02月13日,美国财政部于今年年初颁布的全面实施《2018年外国投资风险审查现代化法案》(Foreign Investment Risk Review Modernization Act of 2018)(“FIRRMA”)的两项最终实施条例(“实施条例”)正式生效实施。



2020年07月11日,海外华人企业家联合会生物分会(OCEAN-BIO)将邀请著名国际律师事务所Dorsey & Whitney(德汇律师事务所)合伙人、德汇全美及中国联合业务主席——潘惜唇律师,为大家做“中美投资并购中的国家安全审查和出口管制问题”的主题演

美东时间 2020年7月11日,周六,晚八点
July 11, 2020, Saturday, 8PM, US Eastern Time
Zoom Link: https://us02web.zoom.us/j/8151859178
Zoom ID: 815 185 9178
Mobile:  +13126266799, 8151859178# US (Chicago)
             +19292056099, 8151859178# US (New York)


SAPA 健康投资论坛暨路演六月线上举行 项目资本双向征集

 SAPA-HQ 美中药协SAPA 3 days ago

2020 SAPA Roadshow

2018年以来在大纽约地区名声鹊起, 广受投资人和企业家们喜爱的美中药协(SAPA)旗舰活动 – 2020 SAPA健康产业投资峰会暨项目路演,将因时而变,重新设计为线上和线下两个部分:第一部分为线上部分,包括投资论坛有关投资和创业的主题演讲和讨论,一系列的线上路演,1对1会议。

首轮路演将于2020年6月20日举行。第二部分线下会议将在10月初的SAPA 2020年会上举行。
•  了解最新生物医药的投资和研发最新动态
•  与顶尖的投资人交流互动
•  与天使轮到Pre-IPO的各类投资人和各大药厂的BD高层交流互动,了解投资全周期细节
•  企业家和投资人1对1会面,充分展示/了解项目和交流融资兴趣
•  除了获得投资,还可能有对外授权技术和产品的机会
•  获得SAPA药界资深专家和投资界人士的专业评审和建议
•  与同行交流分享经验心得
•  广结善缘,获得更多潜在的人才与合作伙伴资源
•  全线上活动,无地域限制,低成本参与,会后可观看活动录像


请填写下方的Google form或者QQ survey报名:
• Google form:  
• QQ survey, (如无法使用Google form):

请填写下方的Google form或者QQ survey
•   Google form:
•   QQ survey, (如无法使用Google form):
2020年5月29日,星期五,11:59 pm (EDT)


本次活动稍后将开放观众注册,敬请关注SAPA微信公众号和SAPA LinkedIn主页!
8BTBA Annual Symposium]🔥🔥🔥
因應疫情,今年將改為半天的線上活動,雖然時間縮短,但一樣內容精彩可期,邀請了吉利德藥廠的講者來擔任Keynote speaker。更多資訊將在6月陸續公布,期待跟大家線上見!
👉BTBA Monthly seminarhttps://www.facebook.com/events/842317972853712/

注册链接 https://zoom.com.cn/webinar/register/2915864885850/WN_AlNghXDqQlO36-IP508RPg

2020 World Medical Innovation Forum | Virtual, Interactive, State of the Art | Monday, May 11

Our Mass General Brigham Harvard faculty including front line clinicians, CEOs and top journalists will examine the coronavirus response, the future of medicine, and AI. Reporters from the New York Times, TIME and CNBC will moderate. Added highlights are digital adoption, new infectious disease technology, investment prospects and national security leadership perceptions on health care challenges and opportunities.
Register today for this year’s leading virtual event. There is no charge.

Join Us and Get Answers from a doctor / epidemiologist- What You Need to Know About COVID-19
JOIN at https://harvard.zoom.us/j/861442364
This is a rapidly evolving situation. Many information is confusing and not relevant to yourself. I thought it would be best to have a communication with a physician who experienced SARS outbreak, and then now COVID outbreak. Dr. Lin is an infectious expert, received his medical training from National Taiwan University and doctorate degree from Harvard.
Speaker: , Dr. Hsien-ho Lin, MD, ScD.林先和
8pm -8:15pm sharing (Hsien-ho)
8:15-8:30pm Q&A (general public)
#重量級講者 #Baxter台灣總經理 #數位醫療趨勢 #腹膜透析
隨著破壞性科技如AI、物聯網的應用在醫療照護領域逐一落地,醫療數位化與智慧化已成為未來醫療的趨勢。比翼加速器很榮幸能邀請到國際前十大醫材廠Baxter 臺灣&香港區總經理Gary Wang 來分享 “ Embrace the Digital Healthcare Future”。
Baxter (NYSE:BAX) 為全球前十大醫材廠,主要專注於腎臟與腹膜透析領域。總經理 Gary 將分享當前數位醫療的趨勢,並進一步介紹Baxter 如何在數位醫療領域創新及結合數據打造更好的醫療服務。
Gary Wang 在醫療領域有長達25年的豐富經驗,除了Baxter 外曾任職於GSK、楊森藥廠、SANOFI。同時Gary也是香港科研製藥協會 (The Hong Kong Association of the Pharmaceutical Industry) 的成員。更多資訊詳見Gary的LinkedIn: https://www.linkedin.com/in/gary-wong-a1768534/

2019-2020 BTBA Seminar series

  • Sunday, December 8, 2019 at 2 PM – 3:30 PM EST
  • MIT Building E25: Room 119/121

Ming-Ru Wu 吳明儒: Synthetic Genetic Circuits for Cancer Immunotherapy: Turning Cancer Cells Against Themselves
Yu-Ru Lee 李育儒: Targeting PTEN Dimerization and Selective Ubiquitination for Cancer Therapy

Jim Chou 周駿:
Plotting against cancer: which killers to hire?
Zhongyou Li 李忠佑:
The immune regulatory effect of a 5' tRNA half in outer membrane vesicles induced by tobramycin

Vicky Chen-ching Yuan 袁禎璟
Zoe Liu 劉紀秀

Po-Cheng Lin 林柏成
Szu-Ta Chen 陳思達

Fan-Yun Lan 藍凡耘
Ying-Chih Lo 羅盈智

I-Cheng Ho 何宜虔
Chi-Hua Yu 游濟華

Pin Kuang Lai 賴品光
Jason Lu 盧彥君

Chia-En Lien 連加恩
Chi-An (Annie) Cheng 程吉安


11th MDDI
Precision Medicine

The 11th CABA Medical Device and Diagnostics Innovation Symposium (MDDI), co-sponsored by NECINA and HMS CSSA, is scheduled for Saturday, December 14th, 2019 at the Conference Center at Waltham Woods, 860 Winter St, Waltham, MA 02451.  

The annual MDDI Symposium is a major CABA event that attracts prominent entrepreneurs, investors, biotech and pharmaceutical executives, academic and industry scientists, as well as professionals in the legal, financial, and healthcare industries, both locally and internationally. Past symposiums were extremely well attended. More than 200 professional attendees will be expected.

The theme of this symposium is “Precision Medicine”. Tailoring medical treatment to the individual characteristics of each patient not only has the potential for better therapeutic outcomes, but also provides crucial information for healthcare decision-making. A holistic assessment of patients' data, including genomic, epigenetic, and clinical information, will offer great insights on and better approaches to effective treatment. Topics of the symposium will include classification of human cells into subpopulations for CAR-T therapy, application of AI in kidney pathologic diagnosis, and novel biomarkers on clinical mass spectrometry for better maternity diseases management. 

  • John Hallinan, MassBio Chief Business Officer
  • Wilson Zhang, CEO/ Milu Labs
  • Regina Au, Principal, New Product Planning/Strategic Planning, BioMarketing Insight
  • Mingru Wu, Cancer Immunology & Virology; Dana-Farber Cancer Institute, Member of Faculty Department of Immunology; Harvard Medical School
  • Shen Luan, Senior Director, Thermofisher Science
  • Allena J. Ji, Director of Clinical Mass Spectrometry Laboratory, Sanofi

Symposium  December 4th, 2019, Boston, USA  “Gene Regulation in Differentiation and Cancer” Agenda 
        8:45-9:15 Registration and Continental breakfast 
        9:15-9:30     Opening Remarks         Alan Rosmarin, M.D. 
        9.30-11:15              Session I:     Chair: Dr. Alan Rosmarin   9.30-10:00   Keynote Speaker Jonathan Licht M.D.  Director- The University of Florida Health Cancer Center,  The Marshall E. Rinker, Sr. Foundation and David B. and Leighan R. Rinker Chair             Disorders of histones and histone methylation in cancer  
       10:00 to 10:15         Ulrich Steidl, M.D. Ph.D.                Lineage Commitment and Differentiation – 15 years later 
  10:15-1:30   Shannon Elf, Ph.D.             Identifying novel molecular dependencies in CALR-mutated myeloproliferative neoplasms  
             10:30-10:45               Huimin Chen, M.D. Ph.D.                        3D Bioprinting Application in Cartilage Repair 
10:45-11:00               Annalisa DiRuscio, M.D. Ph.D.                RNAs: the real writers of the epigenetic code 
11:00-11:15               Sophia Adamia, Ph.D.                             AML epigenetics for the 21st century: novel biomarkers and drug targets 
  11:15-12:30   Session II                Chair: Dr. Ulrich Steidl 
11:15-11:30               Dong-Er Zhang, Ph.D.                    Dynamics of RASSF2 in leukemogenesis 
11:30-11:45               Justin Wheat, Ph.D.                Single Molecule Analysis of Spi1 Transcription Dynamics During Differentiation 
11:45-12:00               Meritxell Alberich-Jorda, Ph.D.                Chronic inflammation, stem cells and leukemia 
12:00-12:15               Britta Will, Ph.D.                Novel safeguards of hematopoietic stem cell identity 
12:15-12:30               Barbara Wegiel, Ph.D. Scavenging of free heme by hemopexin is a key check-point in cancer growth and     metastases 
12:30-1:30               Lunch break 
1:30-3:30               Session III               Chair: Dr. Dong-Er Zhang 

 1:30-2:00              Keynote Speaker              David Livingston, M.D.,  Deputy Director, Dana-Farber/Harvard Cancer Center  Chief, Charles A. Dana Division of Human Cancer Genetics Emil Frei Professor of Genetics and Medicine,   Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts              En route in a normal mammary epithelial cell to BRCA1 breast cancer 
2:00-2:15               Dan Costa, M.D., Ph.D. Dan Tenen and lung cancer: an accidental encounter that helped revolutionize precision    oncology 
2:15-2:30               Gang Huang, Ph.D. Pseudohypoxia - An Underlying Mechanism and therapeutic Target of Myelodysplastic Syndromes 
       2:30-2:45               Hideyo Hirai, MD. Ph.D.                   C/EBPbeta isoforms regulate hematopoietic stem cells under stress condition 
 2:45-3:00               Philipp Staber, MD. Ph.D.                   Identifying functional switches in hematologic malignancies 
3:00-3:15               Rob Welner, Ph.D.                   Targeting Leukemia through the Marrow Microenvironment 
3:15-3:30               Anne Satterthwaite, Ph.D.                   Signals controlling plasma cell accumulation and autoantibody production in lupus 
3:30-3:45               Coffee Break          
3:45-5:30               Session IV               Chair: Dr. Dan Costa 
       3:45-4:00               Alan Rosmarin, MD.                                         A tribute to Dan Tenen 
4:00-4:15               Elena Levantini, Ph.D.  Identification of a targetable KRAS-mutant epithelial population in NSCLC 
      4:15-4:30               Li Chai, M.D.                  Targeting SALL4 in Cancer 
4:30-4:45               Omid Harandi, Ph.D. MRNA-based Engineering of Red Cell Therapeutics (RCTs) to Generate Potent, Allogeneic Cellular Therapies 
4:45-5:00               Bon Trinh, Ph.D.                   RNA Regulation of Promoter-Enhancer Communication  
5:00-5:15               Balazs Halmos, MD. Ph.D.                   Precision lung cancer medicine- a "personal" journey 
5:15-5:45              Closing ceremony              Daniel G. Tenen, M.D.  
5:45-6:00              Group Picture 
6:00-8:30              Dinner party (Invited only) 

Honoring Daniel G. Tenen, M.D.  
For his many contributions to the scientific community 
 Date: Wednesday December 4th, 2019    
 Time: 8:45am – 6:00pm 
 Location: DFCI Jimmy Fund Auditorium Binney Street, Boston, MA, 02115 
Symposium Committee Co-Chairs   Alan G. Rosmarin, M.D. Deputy Editor of Hematology at UpToDate Chief Mission Officer, the Samuel Waxman Cancer Research Foundation.   Dong-Er Zhang, Ph.D. Professor of Pathology and Biological Sciences University of California San Diego Moores UCSD Cancer Center La Jolla, CA   Ulrich Steidl, M.D., Ph.D. Professor of Cell Biology and Medicine, Albert Einstein College of Medicine - Montefiore Medical Center New York, NY   Daniel Costa, M.D., Ph.D. Associate Professor of Medicine, Harvard Medical School Co-director Lung cancer research program within Cancer Research Institute at BIDMC Co-leader of the lung cancer program at Dana-Farber/Harvard Cancer Center 
Symposium Organizing Committee Contacts:  gang.huang@cchmc.org lchai@bwh.harvard.edu pu.zhang@Novartis.com 

Special Talk//台灣大學農學院 盧虎生 院長:台灣農業的現況: 生物經濟及智慧農業
Friday, November 15, 2019 at 5:30 PM – 7:30 PM EST
TMEC 250 mini amphitheater, 260 Longwood Ave, Boston, MA 02115

*講者: 臺灣大學生物資源暨農農學院長盧虎生教授
*講題: 台灣農業的現況: 生物經濟及智慧農業

*時間: 11/15/19 (Fri) 5:30 pm

*地點: Harvard Medical School TMEC 250 Mini amphitheater

(260 Longwood Ave, Boston, MA 02115)


Chinese Scientists and Scholars Association at Harvard Medical School
微信公众号: hmscssa
(添加好友后可由助手号邀请加入 HMS-CSSA 学术群、HMS-CSSA 生活群)


 Jo Lee CABA

2019 Chinese-American BioMedical Association (CABA) Investment and Entrepreneurship (IE) Symposium
Boston Marriott Newton 
2345 Commonwealth Avenue 
Newton, Massachusetts 02466 USA
Nandita Shangari, Ph.D.       Principle, Novartis Venture Fund
Brian Gallagher, Ph.D.   Partner, Abingworth
Hong Cheng, Ph.D.     Head of Research Strategy, Sanofi
Lixin Shen, Ph.D.     Founder and Chief Executive Officer, Guangzhou Alagen PharmTech
Yihan Wang, Ph.D. Founder and Chief Executive Officer, Shenzhen TargetRx, Inc.
Yongzhong Wang, Ph.D.      Chief Executive Officer, CMAB Biopharma
Linda Ji, J.D.     Partner, McDermott Will & Emery
Hugh Davis, Ph.D. Chief Business Officer, Frontage Laboratories, Inc
Jens Stephan, Ph.D.      Professor, East Michigan University
Dapeng Sun, Ph.D. Chief Technology Officer, ABclonal Technology
John Giszczak Vice President, Business Development MORE Health
Shaoyu Chang, M.D.    Vice President, FC Capital
Pengpeng Li, Ph.D.  Analyst, 5AM Ventures
Joe Zhou, MBA  Fouding Partner, BAC Investment
Hongkai He      Venture Partner, Skylight Investment
Jianying Shi, Ph.D.  Vice President, HD Biopharmaceuticals
Michael Zhao    Founder, QTang Ventures
CABA is a 501(C)(3) not-for-profit professional organization registered in Massachusetts since May 2007. CABA is committed to promote public awareness of advancement in the pharmaceutical and biomedical industry, professional interactions in the fields of life sciences, global biomedical innovations and business development.
Chinese-American BioMedical Association
The 2019 BTBA symposium will be held on August 3-4th at Harvard University Northwest Science Building, Cambridge, MA. This event will feature more than 20 speakers, including experts who lead clinical development activities in human diseases, and professionals in the field of gene regulation and molecular immunology. We have crafted an agenda that includes inspiring presentations and interactive forums focused on the novel technologies in synthetic biology, penetrating insights into biotech environments around the US and practical experiences about how to survive in academia/industry. No matter you are biotech entrepreneurs, professionals or students, you can find what you need to advance your future career in here. Please join our annual symposium by registering here>>>

👉👉👉👉👉Ticket: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

👍👍For more information, please visit our website: http://btbatw.org/2019/website

一年一度的BTBA symposium開放售票囉!!
來自各個領域的專家 數十載企業實戰經驗 透徹犀利的職場分析 全部無私分享給你
時間: 2019 Aug 3-4th
地點: Harvard University Northwest Science Building
🎈🎈🎈報名連結: https://www.eventbrite.com/e/btba-annual-symposium-tickets-62120152047?fbclid=IwAR0lv0YFyLwqTqeEv_NcEUrwqFvqDlX8QX3RK5ysjAaTjeusW-Url-qrHGA

2019 SAPA-NE 21st Annual Conference
Deliver Optimal Medicines to All Patients
(Boston Cambridge Marriott, June 8th, 2019)

秉承20年发展壮大的辉煌,胸怀治愈人类疾患的梦想,新英格兰美中医药开发协会SAPA-NE将于2019年06月08日在Boston Marriott Cambridge 宾馆 (50 Broadway, Cambridge, MA) 隆重举行第21届年会。届时,学术精英、企业领袖、投资英才、药界同仁等将云集全球医药创新的圣地—波士顿剑桥,围绕Developing and Delivering the Advanced Medicines to All Patients 的会议主题展开学术交流、共同探讨人类医药事业发展之未来。欢迎光临,敬请注册。
Upcoming Event: 2019-06-08 SAPA-NE 21st Annual Conference: Deliver Optimal Medicines to All Patients
Selected keynote speakers:
* Edward Hu, Co-CEO, WUXI AppTec
* Sridaran Natesan, PhD, Vice President, Sanofi
* X. Shirley Liu, PhD, Professor at Dana–Farber Cancer Institute and Harvard T.H. Chan School of Public Health
* Brad Loncar, CEO, Loncar Investments
* Shi Wenzhao, President of Digital China Health Technologies Corporation Limited
* Shaun R. Coughlin, MD, PhD, VP, Global Head of Cardiovascular and Metabolism at Novartis
SAPA-NE 2019 年会将集中探讨医药行业前沿,热门人工智能,大数据分析,先进肿瘤免疫疗法,多重治疗模式,等等话题。会议还将组织CEO论坛,与大家面对面分享经验。精彩不容错过,欢迎光临,敬请注册:https://www.sapa-neweb.org/ac2019 (早鸟截至日期:5/17/2019:https://www.sapa-neweb.org/ac2019event )
Speaker介绍:Gregory Verdine博士
FogPharma由生物技术领域知名连续创业家、哈佛大学终身教授Gregory Verdine博士创立。这家新锐公司致力于突破现有的常规手段,找到全新的新药分子。其核心技术是Verdine教授在哈佛大学研发的新型技术- 可穿透细胞的迷你蛋白(CPMP)。它有望靶向“不可成药”的靶点,为新药发现与研发带来变革。
除了FogPharma之外,Greg Verdine博士还创办并领导了LifeMine Therapeutics,该公司创建了首个基于真菌基因组的药物开发平台,可以高效快速开发新药。LifeMine Therapeutics和FogPharma总部都设在马萨诸塞州剑桥,并于2016年成立。Verdine博士因其在生涯中担任生命科学家,企业家,投资人和首席执行官的成功角色而得到高度评价。他是哈佛大学和哈佛医学院的Erving教授,先后创建了多家纳斯达克上市的生物技术公司,包括Wave LifeSciences,Enanta,Eleven Bio,Variagenics,Tokai,Aileron和一家私有公司Gloucester制药公司,由Celgene于2010年收购。

Sino-American Pharmaceutical Professionals Association
New England (SAPA-NE)
High School Excellence Scholarship Program

The applicant must meet the following criteria:
  1. The applicant must be a United States citizen or legal resident alien residing in the New England area (MA, NH, RI, VT, CT, ME).
  2. The applicant must be a graduating high school senior with a GPA of 3.3 (out of 4.0) or greater and an SAT score above 1450 (out of 1600) or equivalent.
  3. The applicant must be enrolling for the first time in a full-time undergraduate course of study at an accredited 4-year college or university in the upcoming academic year. The applicant should pursue or intend to pursue a major related to life sciences.
  4. Members of SAPA-NE Board of Directors, the SAPA-NE Advisory Committee, or the SAPA-NE Scholarship Selection Committee cannot participate on the selection process. Any member of the SAPA-NE Executive Committee must disclose should his or her relative become an applicant. Failure to disclose a position of conflict of interest will not only disqualify the candidate, but also lead to disciplinary action towards the executive member.

Application procedures
Application materials
The applicant must submit:
  1. A brief resume illustrating major accomplishments during the applicant’s K-12 education
  2. An essay (~600 words) to illustrate what the applicant will be pursuing at college and what inspired him or her to make such a decision
  3. A recommendation letter from the school counselor and two letters of recommendation from teachers who can attest and comment on the applicant's achievements and development potentials
  4. A copy of high school transcript and a copy of standard test results.
  5. A copy of acceptance letter from the college the applicant intends to enroll
  6. An application fee ($30) needs to be submitted along with the application. Please make any checks payable to SAPA-NE. The application fee can be waived if the applicant’s parent or legal guardian is a member of SAPA.

Online application form is available: http://www.sapa-neweb.org/scholarship-application/. You may fill in the online application form, print the application, and send the application along with recommendation letters, a copy of acceptance letter from the college, and application fee to the following address.
Application Deadline
May 17, 2019 (Postmarked)
Application Mail Address:
Please enclose ALL the materials, including sealed recommendation letters, in ONE package and send to SAPA-NE:
SAPA-NE High School Excellence Scholarship
12 Arbor Lane, Winchester MA 01890
Email Addresses:
Please notify Drs. Huo Li and Guiqing Liang after you send out the application
Huo Li: huoli2@gmail.com;  Guiqing Liang: lianggq1@gmail.com
Selection Procedures
An independent Scholarship Selection Committee appointed by the SAPA-NE Executive Committee will evaluate all valid applications and nominate several strongest candidates. SAPA-NE Executive Committee will make the final selection of up to three award recipients.
Applicants will be evaluated on:
  1. Academic performance, leadership quality, and community/school service.
  2. Demonstrated potential and commitment to a career aspiration that has a broad impact in the society.
Award Acceptance
Recipients of 2019 SAPA-NE High School Excellence Scholarship will be notified by Scholarship Selection Committee by email and will also be posted at SAPA-NE homepage http://www.sapa-neweb.org/scholarship.

Upon contact by Scholarship Selection Committee, a SAPA-NE Scholar must submit an acknowledgment letter stating the acceptance of the scholarship award. The recipients (required) and their parents/legal guardians (optional) will attend the 2019 SAPA-NE High School Excellence Scholarship Award Ceremony at 21st SAPA-NE Annual Conference on June 8, 2019 at Boston Marriott Cambridge, Cambridge MA. A short speech (5 minutes) made by each award recipient will be expected at the ceremony. Each recipient will be awarded up to $1000 one-time scholarship.
2019 Boston BioForum (CABA) Driving Transformation in Life Sciences Industry
2019波士顿生物医药论坛| CABA
Date and time: Saturday, May 4, 2019 @ 8AM EST
The Westin Waltham Boston
70 3rd Ave, Waltham, MA 02451

The goal of the annual conference is to invite prominent entrepreneurs, investors, biotech and pharma executives, academic and industry scientists, as well as professionals from the legal, finance, and healthcare fields to talk about hot topics in the Life Science industry.
  • Future of Immuno-Oncology
  • Outlook of Cell & Gene Therapy
  • AI & Big Data in Health
  • Evolving Landscape for Life Science Investment
  • Next Big Thing in Biotech & Pharma

  • Will Brownsberger
    MA State Senator

  • Jos Melenhorst
    Director, CAR-T Product Development
    University of Pennsylvania

  • Jonathan Terrett
    Head of Immuno-Oncology
    CRISPR Therapeutics

  • Sadik Kassim
    Executive Director
    Kite Pharma

  • Nenard Grmusa
    SVP, Head of External Innovation

  • Lei Xiao
    Innovative Cellular Therapeutics

  • Derrick Li
    Head of Strategy and Investor Relations
    Cellular Biomedicine Group

  • Nick Valiante
    Founder and CEO
    Glyde Bio

  • F. Stephen Hodi
    Directot, Center for IO
    Dana Farber Cancer Institute, Harvard Medical School

  • William Cao
    GraCell Bio

  • Weichang Zhou
    Chief Technology Officer
    Wuxi Biologics

  • Scott Brown
    Computational Chemistry

  • Catherine Sabatos-Peyton
    Novartis Institutes for BioMedical Research



欢迎大家参加哈佛大学2019年华人生物医学年会!本次学术年会将于4月28日(周日)在波士顿儿童医院召开 。参会报名请见文末注册链接(.edu 邮箱注册免费)。



Harvey Lodish
Ed Boyden